<DOC>
	<DOCNO>NCT02506647</DOCNO>
	<brief_summary>This Phase 1 , exploratory , single dose , randomize , double-blind , two-way cross , pilot , glucose clamp study assess pharmacokinetic pharmacodynamic effect Gan &amp; Lee 's insulin glargine injection comparison market Lantus ( US ) subject type 1 diabetes mellitus ( T1DM ) .</brief_summary>
	<brief_title>PK/PD Study Gan &amp; Lee 's Insulin Glargine Injection Comparison Lantus Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>1 . Female Male subject T1DM , duration ≥12 month . 2 . Adults ≥ 18 ≤ 65 year age . 3 . Body mass index ( BMI ) ≥ 18.5 ≤ 30.0 kg/m2 . 4 . Weight ≥ 50 kg . 5 . Fasting serum Cpeptide ≤ 0.4 nmol/L , assess plasma glucose concentration &gt; 90mg/dL . 6 . HbA1c ≤ 9.5 % . 7 . Current stable treatment insulin ( consistent therapy multiple daily injection basal bolus insulin CSII ) . 8 . Current stable dose insulin ( ± 20 % difference total daily insulin dose ) 2week period prior screen ; total daily dose ≤ 1.2 IU/kg . 9 . Female subject must nonpregnant nonlactating . For postmenopausal female ( menses &gt; 12 month ) ; postmenopausal status confirm test FSH level ≥ 40 IU/mL screen subject &lt; 55 year age . 10 . Ability provide write informed consent . 1 . A subject proliferative retinopathy maculopathy , severe gastroparesis , and/or severe neuropathy , particular autonomic neuropathy , judge Investigator . 2 . History ≥ 2 episode severe hypoglycemia ( define per ADA criterion ) ≥ 1 episode diabetic ketoacidosis emergency room visit uncontrolled diabetes lead hospitalization within 6 month prior screen . 3 . Subjects carbohydrate restrict diet ( i.e. , diet &lt; 100 gram per day carbohydrate ) . 4 . Systolic blood pressure &gt; 160 mmHg and/or diastolic blood pressure &gt; 95 mmHg screening . Treatment 2 antihypertensive medication must stable dos least 3 month prior screen . 5 . Current use drug ( insulin ) know interfere glucose insulin metabolism , include limited oral corticosteroid , monoamino oxidase ( MAO ) inhibitor , growth hormone nonselective βblockers , loop diuretic . 6 . Thyroid hormone use stable past 3 month prior dose . 7 . Hyperlipidemia treatment stable dose ≥ 3 month prior dose . ( HMGCoA reductase inhibitor ( statin ) , fibrate ( i.e . fenofibrate , gemfibrozil ) ezetimibe allow treatment ) . 8 . Any use nonsteroid antiinflammatory drug ( NSAIDs ) except lowdose Aspirin allow within 7 day prior dose dose day . 9 . Participation investigational study within 30 day prior dose 5 halflives within last dose investigational product whichever longer . 10 . History major surgery within 6 month prior screen . 11 . History serious adverse reaction hypersensitivity insulin , insulin analogue , product component , chemically related product . 12 . History renal disease abnormal kidney function test screen ( glomerular filtration rate ( GFR ) &lt; 60 mL/min/1.73m2 ) . 13 . Clinically significant abnormal hematology biochemistry screen test . 14 . Any history heart disease , define symptomatic heart failure ( New York Heart Association class III IV ) , myocardial infarction , coronary artery bypass graft surgery , angioplasty , unstable angina require medication , transient ischemic attack , cerebral infarct , cerebral hemorrhage . 15 . History clinically significant gastrointestinal , cardiovascular , hematological , psychiatric , renal , hepatic , pancreatic neurological abnormality judge Investigator . 16 . Personal family history hypercoagulability thromboembolic disease . 17 . History active infection , mild viral illness within 30 day prior dose judge Investigator . 18 . History alcohol illicit/recreational drug abuse judge Investigator within approximately 1 year . ( Use 1000 mL beer , 500 mL wine , 100 mL distil spirit allow ) . 19 . Smoking &gt; 10 cigarette equivalent use tobacco product ( e.g.nicotine patch ) within 6 month prior Screening . Subjects must able refrain smoke least 1 week prior admission inhouse period . 20 . Known history hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCV Ab ) , human immunodeficiency virus type 1 ( HIV1 ) 2 ( HIV2 ) antibody . 21 . Existence surgical medical condition , judgment Investigator , might interfere absorption , distribution metabolism drug tolerability/safety measurement . 22 . Presence clinically significant physical , laboratory , electrocardiogram ( ECG ) finding ( e.g. , QTcF &gt; 470 msec female , &gt; 450 msec male , LBBB ) Screening , opinion Investigator , may interfere aspect study conduct interpretation result . 23 . Donation loss &gt; 500 mL blood blood product within 56 day dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>